Global Nuclear Medicine Market, Forecast and Opportunity Report 2021-2026 –

DUBLIN – (COMMERCIAL THREAD)–The “Global Nuclear Medicine Market, By Type, By Diagnostic Nuclear Medicine, By Therapeutic Nuclear Medicine, By Application, By Diagnostic Applications, By Therapeutic Applications, By End User, By Region, Forecast And Opportunity, 2026” report was added to offer.

The global nuclear medicine market is expected to grow at an impressive rate during the forecast period owing to the increase in the incidence and prevalence of diseases like cancer, initiatives to narrow the gap between the demand and supply of Mo-99 and increasing research and development in radiotherapy to treat various diseases.

In addition, nuclear medicines are widely used in molecular imaging, which is a technique involving molecules as biomarkers of specific molecular processes that determine the onset or progression of disease.

Nuclear drugs are a convenient and safer alternative for patients to x-rays and other external imaging devices. Due to this major factor, chemotherapy methods are replaced by radiopharmaceuticals or nuclear drugs for the treatment of cancer.

They are also used in applications such as lymphoma and bone metastases. Some of the nuclear drugs used in diagnostic procedures are F-18, Tc-99, Ga-67 and I-123 while I-131, Ir-192, Y-90, I-125, Lu-177 and Ra- 223 are used in therapeutic procedures. These factors are predicted to drive the global nuclear medicine market up to 2026.

Apart from the above-mentioned growth factors, the global nuclear medicine market is also facing certain restraints. The short half-life of nuclear drugs or radiopharmaceuticals reduces their potential adoption. Other limiting factors include supply shortages, logistical difficulties and the limited number of qualified medical personnel.

The global nuclear medicine market is segmented on the basis of therapy, type, application, therapeutics, route of administration, end user, and region. Based on type, the nuclear medicine market is segmented into diagnostic nuclear medicine, therapeutic nuclear medicine, and brachytherapy isotopes.

Diagnostic nuclear medicine can be further divided into SPECT radiopharmaceuticals and PET radiopharmaceuticals. The SPECT radiopharmaceuticals segment represents the largest market share and is expected to retain its dominance in the coming years due to its low cost and wide use in different applications.

The major market players are implementing activities such as product development, business expansion and collaborative development to retain a significant share of the nuclear medicine market.

The major players operating in the global nuclear medicine market include

  • Cardinal Health, Inc

  • GE Healthcare

  • Curium SAS

  • Lantheus Medical Imaging, Inc

  • Bayer AG

  • Bracco Imaging SpA

  • Nordion Inc

  • Novartis AG (Advanced Accelerator Applications SA)

  • Isotopy Molecular Imaging Limited

  • NorthStar Medical Radioisotopes, LLC

Scope of the report:

Years considered for this report:

  • Historical years: 2016-2019

  • Baseline year: 2020

  • Estimated year: 2021

  • Forecast period: 2022-2026

Global Nuclear Medicine Market, By Type:

  • Diagnostic Nuclear Medicine

  • SPECT radiopharmaceuticals

  • PET radiopharmaceuticals

  • Therapeutic Nuclear Medicine

  • Alpha transmitters

  • Beta emitters

  • Brachytherapy isotopes

Global Nuclear Medicine Market, By Application:

  • Diagnostic applications

  • SPECT applications

  • PET applications

  • Therapeutic applications

  • Thyroid indications

  • Bone metastasis

  • Lymphoma

  • Endocrine tumors

  • Others

Global Nuclear Medicine Market, By End User:

  • Hospitals and clinics

  • Diagnostic centers

  • Academic and research institutions

For more information on this report, visit

About Clara Barnard

Check Also

Eliminate the sting of cryptocurrencies

scaliger/iStock Editorial via Getty Images Introduction Faced with structurally slower long-term economic growth cause by …